IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 198 filers reported holding IMPAX LABORATORIES INC in Q4 2015. The put-call ratio across all filers is 0.81 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,938,000 | +18.5% | 151,134 | +1.5% | 0.00% | 0.0% |
| Q4 2017 | $2,480,000 | -17.9% | 148,859 | +0.3% | 0.00% | 0.0% |
| Q3 2017 | $3,019,000 | +31.7% | 148,419 | +4.2% | 0.00% | 0.0% |
| Q2 2017 | $2,292,000 | +37.4% | 142,452 | +8.1% | 0.00% | +100.0% |
| Q1 2017 | $1,668,000 | -3.9% | 131,834 | +0.5% | 0.00% | -50.0% |
| Q4 2016 | $1,736,000 | +9.4% | 131,224 | +95.7% | 0.00% | 0.0% |
| Q3 2016 | $1,587,000 | +250.3% | 67,046 | +326.4% | 0.00% | – |
| Q2 2016 | $453,000 | -9.8% | 15,722 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $502,000 | -18.1% | 15,722 | +10.4% | 0.00% | 0.0% |
| Q4 2015 | $613,000 | +31.5% | 14,241 | +5.0% | 0.00% | 0.0% |
| Q3 2015 | $466,000 | -21.8% | 13,557 | +4.4% | 0.00% | 0.0% |
| Q2 2015 | $596,000 | +2.1% | 12,985 | +3.9% | 0.00% | 0.0% |
| Q1 2015 | $584,000 | +79.1% | 12,497 | +22.8% | 0.00% | – |
| Q4 2014 | $326,000 | +29.9% | 10,175 | -2.0% | 0.00% | – |
| Q3 2014 | $251,000 | – | 10,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 5,415,600 | $162,414,000 | 1.91% |
| Broadfin Capital, LLC | 1,217,858 | $36,524,000 | 1.80% |
| NEW AMSTERDAM PARTNERS LLC/NY | 695,100 | $20,846,000 | 1.36% |
| Healthcare Value Capital, LLC | 50,000 | $1,500,000 | 1.26% |
| Iguana Healthcare Management, LLC | 75,000 | $2,249,000 | 1.05% |
| Matarin Capital Management, LLC | 78,292 | $2,347,977,000 | 1.04% |
| Independence Capital Asset Partners, LLC | 253,089 | $7,590,000 | 1.04% |
| Tekla Capital Management LLC | 344,683 | $10,337,000 | 0.95% |
| Penn Capital Management Company, LLC | 794,641 | $23,831,000 | 0.92% |
| Leonard Capital Management, Inc. | 87,661 | $2,629,000 | 0.89% |